New flu vaccine candidate enters human testing
NCT ID NCT07340047
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial compares an experimental flu vaccine called H1ssF with the standard seasonal flu vaccine (Flucelvax). About 112 adults aged 18-70 will take part, including some who have had flu shots before and some who have never had one. The main goal is to check safety and how well the body's immune system responds to the new vaccine.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts